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Background: The prognostic impact of preadmission use of calcium channel blockers (CCBs) and beta blockers
(BBs) on stroke mortality remains unclear. We aimed to examine whether preadmission use of CCBs or BBs was
associated with improved short-term mortality following ischemic stroke, intracerebral hemorrhage (ICH), or
subarachnoid hemorrhage (SAH).
Methods: We conducted a nationwide population-based cohort study using Danish medical registries. We identified
all patients with a first-time inpatient diagnosis of stroke between 2004 and 2012 and their comorbidities. We defined
CCB/BB use as current use, former use, or non-use. Current use was further classified as new or long-term use. We used
Cox regression modeling to compute 30-day mortality rate ratios (MRRs) with 95% confidence intervals (CIs), controlling
for potential confounders.
Results: We identified 100,043 patients with a first-time stroke. Of these, 83,736 (83.7%) patients had ischemic stroke,
11,779 (11.8%) had ICH, and 4,528 (4.5%) had SAH. Comparing current users of CCBs or BBs with non-users, we found
no association with mortality for ischemic stroke [adjusted 30-day MRR = 0.99 (95% CI: 0.94-1.05) for CCBs and 1.01
(95% CI: 0.96-1.07) for BBs], ICH [adjusted 30-day MRR = 1.05 (95% CI: 0.95-1.16) for CCBs and 0.95 (95% CI: 0.87-1.04) for
BBs], or SAH [adjusted 30-day MRR = 1.05 (95% CI: 0.85-1.29) for CCBs and 0.89 (95% CI: 0.72-1.11) for BBs]. Former use
of CCBs or BBs was not associated with mortality.
Conclusions: Preadmission use of CCBs or BBs was not associated with 30-day mortality following ischemic stroke, ICH,
or SAH.
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Stroke is one of the most disabling neurological diseases
[1]. It is expected to remain the second leading cause of
death worldwide, exceeded only by myocardial infarction
[1-3]. From 1999 to 2009, the annual incidence of first-
time stroke was approximately 600,000 cases in the United
States [4]. Thirty-day mortality is approximately 11% for is-
chemic stroke [5], 34% for intracerebral hemorrhage (ICH)
[5], and 29% for subarachnoid hemorrhage (SAH) [6].* Correspondence: jens.sundboll@clin.au.dk
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unless otherwise stated.Calcium channel blockers (CCBs) and beta blockers
(BBs) are commonly used antihypertensive agents [7]. It
has previously been established that elevated pread-
mission blood pressure is associated with markedly in-
creased stroke mortality [8]. Because the association
between blood pressure at hospitalization and mortality
is U-shaped in stroke [9], and both ischemic and
hemorrhagic strokes are associated with transiently ele-
vated blood pressure in the acute phase [10], we hypoth-
esized that preadmission use of CCBs or BBs could
reduce short-term mortality through improved blood
pressure control.
It is well established that CCBs and BBs reduce stroke
risk in persons with hypertension [11], but it remainsal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tality following stroke. In a recent study, it was estab-
lished that angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers were associated with re-
duced 30-day mortality following ischemic stroke but
not haemorrhagic stroke [12]. To investigate whether
this protective effect extended to other antihypertensive
agents, we examined whether use of CCBs or BBs at
time of stroke was associated with reduced short-term
mortality.Methods
Setting
We conducted this nationwide population-based cohort
study in Denmark. During the study period (1 July 2004
to 31 December 2012), the total underlying population
at risk was 6,379,918 inhabitants. The study period com-
menced 6 months after establishment of the Danish Na-
tional Database of Reimbursed Prescriptions (DNDRP)
on 1 January 2004, to ensure availability of at least
6 months of preadmission prescription history for all
participants [13]. The Danish National Health Service
provides universal tax-supported health care, guaranteeing
unfettered access to general practitioners and hospitals
and partial reimbursement for prescribed medications, in-
cluding CCBs and BBs [13]. We linked medical registries
using the unique central personal registry number
assigned to every Danish citizen at birth and to residents
upon immigration [14].Patients with stroke
In Denmark, care for patients with stroke and other
medical emergencies is provided by public hospitals [15].
We used the Danish National Registry of Patients
(DNRP), covering all Danish hospitals [16], to identify all
patients with a first-time inpatient hospitalization for
stroke during the study period. Because more than two-
thirds of all unspecified strokes (International Classifica-
tion of Diseases (ICD-10) code: I64) are known to be is-
chemic strokes (ICD-10 code: I63) [17], we classified
unspecified strokes (32% of all stroke diagnoses [12]) as
ischemic strokes. The DNRP contains data on admission
and discharge dates and discharge diagnoses from all
non-psychiatric hospitals since 1977 and on emergency
room and outpatient clinic visits since 1995 [16]. Each
hospital discharge is assigned one primary diagnosis and
up to 19 secondary diagnoses classified according to the
International Classification of Diseases, 8th revision
(ICD-8) until the end of 1993 and 10th revision (ICD-
10) thereafter [16]. We identified patients using both
primary and secondary diagnoses for ischemic stroke,
ICH, and SAH.CCB and BB use
We used the DNDRP to identify all prescriptions redeemed
for CCBs and BBs by study participants [13]. Pharmacies
in Denmark are equipped with electronic accounting sys-
tems, primarily used to secure reimbursement from the
National Health Service. For each redeemed prescription,
the patient’s central personal registry number, the amount
and type of drug prescribed according to the Anatomical
Therapeutic Chemical (ATC) classification system, and the
date the drug was dispensed are transferred electronically
from the pharmacies to the DNDRP [13].
We defined current users as patients whose last pre-
scription redemption for CCBs or BBs was <90 days be-
fore hospital admission for stroke. We chose an exposure
window of 90 days to identify most current users, as pre-
scriptions of CCBs/BBs are seldom provided for more
than 90 days at a time in Denmark. As the drugs’ effects
and potential side effects may be less pronounced in long-
term users [18], this could lead to underestimation of the
association with mortality [18]. Consequently, current
users were further categorized into new users, who
redeemed their first-ever CCB or BB prescription within
90 days before their admission date, and long-term users,
who redeemed their first-ever prescription more than
90 days before their admission date. We defined former
users as patients whose last prescription redemption was
between 90 and 180 days before admission, and non-users
as patients with no prescription redemption within
180 days before admission.
Mortality
We used the Danish Civil Registration System (CRS) to
obtain information on all-cause mortality [14]. The CRS
has recorded all changes in vital status and migration for
the entire Danish population since 1968, with daily elec-
tronic updates [14].
Patient characteristics
The complete inpatient and outpatient medical history
available in the DNRP [16] provided information on
known prognostic factors (myocardial infarction, atrial
fibrillation or flutter, intermittent arterial claudication,
diabetes, and dementia) [19] and other potential con-
founders (Table 1).
To increase the sensitivity of diagnoses of diabetes,
COPD, and alcoholism-related diseases, we searched the
DNDRP for any previous prescriptions for anti-diabetic
medications, respiratory medications, and alcohol deter-
rents. Relevant ICD and ATC codes are provided in
Additional file 1: Table S1.
Comedication use
We obtained information from the DNDRP on concur-
rent use (last prescription redemption within 90 days
Table 1 Characteristics of stroke patients by preadmission use of calcium channel blockers or beta blockersa
Ischemic stroke (n = 83736) Intracerebral hemorrhage (n = 11779) Subarachnoid hemorrhage (n = 4528)





































Male 47.7 52.2 46.7 52.7 51.8 51.8 51.4 51.7 44.7 42.1 46.2 42.1
Age, years
<60 9.7 20.7 9.2 21.6 12.5 26.0 11.5 27.3 24.1 57.1 24.2 57.5
60-69 19.7 21.9 19.5 22.1 21.0 20.9 20.0 21.0 23.8 20.9 26.6 20.6
70-79 30.8 26.2 30.7 25.9 31.8 25.2 33.3 24.0 25.5 12.6 24.2 12.4
≥80 39.8 31.2 40.5 30.5 34.7 27.9 35.2 27.7 26.6 9.4 24.9 9.4
Comorbidities
Cardiovascular diseases
Congestive heart failure 10.3 7.9 18.6 5.3 9.8 5.6 16.6 3.8 5.2 2.8 15.7 1.6
Myocardial infarction 11.5 8.2 21.6 4.8 11.6 5.3 17.8 3.3 7.1 2.7 18.2 1.4
Angina pectoris 24.7 13.4 33.1 10.0 25.1 10.1 30.4 7.5 21.1 5.7 32.4 4.1
Atrial fibrillation or flutter 19.5 12.1 30.3 8.5 23.6 11.8 38.2 7.5 15.1 4.3 24.7 2.9
Heart valve disease 6.4 4.0 8.6 3.2 6.7 3.7 11.0 2.6 4.7 1.6 6.8 1.3
Intermittent claudication 5.1 2.6 4.9 2.5 4.0 1.5 3.6 1.4 2.7 1.0 2.7 1.0
Venous thromboembolism 4.0 3.7 4.2 3.6 4.6 3.3 4.7 3.2 2.5 2.0 3.9 1.8
Hypertension 50.5 19.3 47.4 18.4 55.3 18.8 52.1 16.7 47.9 10.5 46.0 10.3
Other diseases
Obesity 5.3 3.6 5.4 3.5 7.4 2.7 6.2 2.5 5.2 2.9 5.8 2.7
Diabetes mellitus 20.0 11.7 19.4 11.5 19.1 8.2 18.3 7.5 14.2 4.8 13.3 4.6
Chronic kidney disease 4.8 2.1 5.0 1.8 8.5 2.0 7.0 1.8 6.0 1.0 5.8 1.1
Chronic pulmonary disease 24.4 19.9 21.5 20.5 23.7 18.3 20.6 18.5 28.8 16.8 24.2 17.3
Alcoholism-related disease 4.9 6.8 5.2 6.8 5.8 8.4 6.2 8.4 5.5 7.6 10.4 7.1
Dementia 3.7 3.3 3.2 3.4 4.6 3.9 3.6 4.0 2.2 1.2 2.2 1.3
Cancer 16.2 14.0 16.2 13.9 18.7 15.3 18.6 15.0 16.4 8.0 18.2 7.8
Concurrent medications
Cardiovascular drugs
ACE-Is/ARBs 45.8 21.9 44.9 20.6 43.5 17.3 44.4 15.2 41.1 12.0 45.3 11.4
Beta blockers 31.8 18.0 - - 28.4 14.7 - - 23.6 7.5 - -











Table 1 Characteristics of stroke patients by preadmission use of calcium channel blockers or beta blockersa (Continued)
Diuretics 44.4 24.2 48.8 21.8 40.3 19.0 43.7 16.5 32.6 11.0 39.5 9.9
Nitrates 4.3 1.4 5.2 1.0 3.9 1.0 3.9 0.6 2.5 0.4 3.9 0.1
Statins 28.1 13.7 31.9 11.7 30.8 11.9 31.4 10.3 25.8 8.5 33.9 7.5
Aspirin 38.9 21.1 45.8 18.2 37.7 18.9 42.1 16.5 29.6 8.2 35.1 7.2
Clopidogrel 3.1 1.6 4.7 1.1 3.1 1.3 4.6 0.9 1.9 0.9 4.8 0.5
Vitamin K antagonists 7.7 4.1 10.9 2.9 19.1 8.9 29.0 5.9 8.5 2.9 16.2 1.9
Other drugs
Systemic glucocorticoids 5.8 4.6 5.2 4.7 4.8 3.8 5.2 3.7 6.3 2.4 3.9 2.6
SSRIs 10.6 8.7 10.1 8.7 11.2 9.5 12.7 9.2 9.3 6.9 11.9 6.5
Bisphosphonates 4.0 3.3 4.0 3.3 4.1 3.7 4.5 3.6 5.2 2.3 3.9 2.2
NSAIDs 12.1 10.7 11.2 10.9 11.4 10.2 9.4 10.6 15.1 10.4 11.4 10.8
an = 100,043. Table values are given as %. Data for former users are not shown (n = 2995/3145 among ischemic stroke patients, 339/372 among intracerebral hemorrhage patients, and 112/92 among subarachnoid
hemorrhage patients for calcium channel blockers/beta blockers, respectively). ACE-Is/ARBs indicates angiotensin converting enzyme inhibitors/angiotensin receptor blockers; SSRIs, selective serotonin reuptake inhibitors;
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affect stroke prognosis [13]. Relevant ATC codes are
provided in Additional file 1: Table S1.
Statistical analysis
We characterized the stroke cohort according to sex, age
group (<60, 60–69, 70–79, ≥80 years), individual comor-
bidities, and comedication use. We followed all patients
from hospital admission date until death, emigration, or
30 days of follow up, whichever came first.
We used a Cox proportional-hazards regression analysis
to compute the hazard ratio as a measure of the mortality
rate ratio (MRR) within 30 days of hospital admission for
current, new, long-term, and former use compared with
non-use. The analysis was adjusted for sex, age groups,
and the individual comorbidities and comedications listed
in Table 1. The proportional hazard assumption was
assessed using log–log plots and found valid. We repeated
the analysis stratifying by sex, age group, and presence/ab-
sence of myocardial infarction, congestive heart failure,
atrial fibrillation or flutter, angina pectoris, hypertension,
diabetes, and chronic kidney disease.
We performed four sensitivity analyses. First, to in-
crease the positive predictive value (PPV) of the stroke
diagnosis, we restricted the analyses to patients who had
a computed tomography (CT) or magnetic resonance
imaging (MRI) scan registered in the DNRP during the
stroke admission. Second, to examine the sensitivity of
the estimates to differences in exposure definitions, we
repeated the analysis substituting 60-day and 30-day ex-
posure windows for the 90-day exposure window. Third,
to reduce the potential for confounding by indication for
CCB and BB use, we directly compared current users
with former users. Fourth, we repeated the analysis sep-
arating ischemic stroke into “unspecified stroke” and
“specified ischemic stroke”. Analyses were performed
using SAS version 9.2 (SAS Institute Inc., Cary, NC,
USA). The study was approved by the Danish Data Pro-
tection Agency (record number 2011-41-5755). As this
study did not involve contact with patients or any inter-
vention, it was not required to obtain permission from




Patient characteristics are shown in Table 1. We identi-
fied 100,043 patients with a first-time stroke. Of these,
83,736 (83.7%) patients had ischemic stroke (median
age: 74 years), 11,779 (11.8%) had ICH (median age:
72 years), and 4,528 (4.5%) had SAH (median age:
58 years). A total of 14,698 patients (14.7%) were current
CCBs users, 3,446 (3.4%) were former users, and 81,899
(81.9%) were non-users. For BBs, the distribution wassimilar with a total of 19,515 (19.5%) current users,
3,609 (3.6%) former users, and 76,919 (76.9%) non-users.
All cardiovascular diseases, obesity, diabetes mellitus,
chronic kidney disease, and use of all cardiovascular
drugs were more common among current users of CCB
and BB in each stroke group than among non-users. Me-
dian age was also higher among current CCB/BB users
than among non-users.
Mortality
Overall 30-day mortality risk among non-users of CCB
or BB was 10% for ischemic stroke, 33-34% for ICH, and
23% for SAH (Table 2). After multivariable adjustment,
current use of CCBs or BBs was not associated with
mortality compared with non-use for ischemic stroke
[30-day MRR = 0.99 (95% confidence interval (CI): 0.94-
1.05) for CCB and 1.01 (95% CI: 0.96-1.07) for BB], for
ICH [30-day MRR = 1.05 (95% CI: 0.95-1.16) for CCB
and 0.95 (95% CI: 0.87-1.04) for BB], or for SAH [30-day
MRR = 1.05 (95% CI: 0.85-1.29) for CCBs and 0.89 (95%
CI: 0.72-1.11) for BBs]. No association with mortality
was found for former use of CCBs or BBs compared
with non-use (Table 2).
We found no substantial modification of the CCB or
BB association (Additional file 1: Table S7). However,
among ICH patients we found a reduction in MRR in
younger users of both CCB (age <60 years) and BB (age
between 60–69 years) although CIs were partly overlap-
ping between age groups.
The results were robust in the analysis restricted to
CT- or MRI-confirmed diagnoses (Additional file 1:
Table S2) and in analyses using a 60-day (Additional file
1: Table S3) and 30-day (Additional file 1: Table S4)
exposure window. Also, when current users were com-
pared directly with former users (Additional file 1: Table
S5) and when “unspecified stroke” and “specified ische-
mic stroke” were analyzed separately (Additional file 1:
Table S6), no association with mortality following ische-
mic stroke, ICH, or SAH was found.
Discussion
In this cohort study with virtually complete follow-up of
100,043 patients hospitalized for stroke, preadmission
use of CCBs or BBs was not associated with 30-day mor-
tality following ischemic stroke, ICH, or SAH. The re-
sults may be generalized to most industrial Western
societies where changes in risk factor modification and
treatment have followed international recommendations.
A number of studies have examined use of CCBs or
BBs after stroke onset. A meta-analysis of 34 random-
ized controlled trials encompassing a total of 7,731 pa-
tients evaluated CCB administration versus control
(placebo or standard medical treatment alone) after is-
chemic stroke onset and reported no beneficial effect on
Table 2 Preadmission use of calcium channel blockers or beta blockers and 30-day mortality estimates following
stroke
Calcium channel blocker Beta blocker
Mortality risk,
% (95% CI)
Mortality rate ratio (95% CI) Mortality risk,
% (95% CI)
Mortality rate ratio (95% CI)
Unadjusted Adjusteda Unadjusted Adjusteda
Ischemic stroke
Non-use 10.3 (10.1-10.5) 1 (reference) 1 (reference) 9.8 (9.5-10.0) 1 (reference) 1 (reference)
Former use 13.1 (11.9-14.3) 1.29 (1.16-1.43) 1.04 (0.94-1.15) 13.0 (11.8-14.2) 1.35 (1.22-1.49) 1.01 (0.91-1.12)
Current use 12.4 (11.9-13.0) 1.22 (1.15-1.29) 0.99 (0.94-1.05) 13.9 (13.3-14.4) 1.45 (1.38-1.52) 1.01 (0.96-1.07)
New use 10.1 (9.1-11.1) 0.97 (0.88-1.08) 0.89 (0.80-0.99) 12.6 (11.6-13.6) 1.31 (1.19-1.43) 0.97 (0.88-1.06)
Long-term use 13.3 (12.6-14.0) 1.31 (1.24-1.39) 1.03 (0.97-1.10) 14.3 (13.7-14.9) 1.50 (1.42-1.58) 1.02 (0.96-1.08)
Intracerebral hemorrhage
Non-use 34.1 (33.2-35.0) 1 (reference) 1 (reference) 33.3 (32.4-34.3) 1 (reference) 1 (reference)
Former use 37.5 (32.6-42.9) 1.11 (0.93-1.32) 0.92 (0.77-1.10) 40.6 (35.8-45.8) 1.29 (1.09-1.52) 1.00 (0.84-1.19)
Current use 41.3 (38.6-44.2) 1.28 (1.16-1.41) 1.05 (0.95-1.16) 41.9 (39.7-44.2) 1.35 (1.25-1.46) 0.95 (0.87-1.04)
New use 36.6 (31.4-42.5) 1.09 (0.90-1.33) 0.95 (0.78-1.16) 41.7 (37.2-46.6) 1.36 (1.17-1.58) 0.96 (0.81-1.12)
Long-term use 42.9 (39.7-46.3) 1.35 (1.21-1.50) 1.09 (0.97-1.22) 42.0 (39.5-44.5) 1.35 (1.24-1.47) 0.94 (0.85-1.04)
Subarachnoid hemorrhage
Non-use 22.6 (21.3-23.9) 1 (reference) 1 (reference) 22.8 (21.6-24.2) 1 (reference) 1 (reference)
Former use 32.2 (24.4-41.7) 1.51 (1.08-2.11) 1.05 (0.75-1.48) 25.0 (17.4-35.2) 1.12 (0.74-1.69) 0.60 (0.38-0.95)
Current use 33.0 (28.4-38.0) 1.56 (1.29-1.89) 1.05 (0.85-1.29) 31.6 (27.3-36.3) 1.46 (1.21-1.75) 0.89 (0.72-1.11)
New use 29.1 (21.0-39.5) 1.38 (0.94-2.02) 0.98 (0.66-1.45) 28.3 (20.5-38.3) 1.24 (0.85-1.81) 0.70 (0.46-1.06)
Long-term use 34.3 (28.9-40.2) 1.62 (1.31-2.01) 1.06 (0.84-1.34) 32.6 (27.7-38.1) 1.53 (1.25-1.88) 0.92 (0.72-1.17)
aAdjusted for sex, age groups, and the individual comorbidities and comedications listed in Table 1.
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are prescribed as a component of vasospasm manage-
ment after SAH onset and another recent meta-analysis
reports more than 50% mortality reduction in SAH pa-
tients receiving this treatment (OR = 0.45, 95% CI: 0.15-
1.29) [21]. As we studied the prognostic effect of CCB or
BB use initiated before and not after hospitalization for
stroke, our neutral results do not necessarily contradict
these findings.
The effect of BB use before ischemic stroke on subse-
quent stroke severity has been examined in two cohort
studies of 111 [22] and 1,375 [23] patients. Both studies
reported a beneficial effect on stroke severity as measured
by the Canadian Neurologic Scale, the National Institute
of Health Stroke Scale [24], or the European Stroke Scale
[25]. Although both studies examined pre-stroke use of
BB, neither included mortality as an outcome measure.
Consequently our results are not directly comparable.
It has recently been established that preadmission use of
angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers reduces the 30-day mortality following
ischemic stroke, whereas there was no association for ICH
and SAH [12]. Our null results for ischemic stroke suggest
that the positive effect of angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers on ischemicstroke mortality is mediated via pathways other than
blood pressure control.
Transient hypertension is a common finding in the
acute phase of stroke, and its management has been sub-
ject of debate [26]. A recent randomized trial of 4,071
patients, which examined the effect of blood pressure re-
duction in the acute phase of ischemic stroke, reported
no difference between treatment groups on mortality up
to 14 days or on major disability (OR = 1.00, 95% CI:
0.88-1.14) [27]. Our study supports a neutral effect of
antihypertensive drug use on mortality following stroke,
although we examined CBB and BB use initiated prior to
stroke onset.
The rise in blood pressure during acute stroke was in-
vestigated in a recent population-based study of 653 pa-
tients with acute ischemic stroke or ICH [10]. Systolic
blood pressure was substantially elevated compared with
usual pre-stroke levels after intracerebral hemorrhage,
whereas acute-phase systolic blood pressure after major
ischemic stroke was only marginally raised. This sug-
gests that the benefits of lowering blood pressure acutely
after stroke might be expected to differ, favoring ICH
[10]. Consistent with this interpretation, our results do
not exclude a protective effect of preadmission use of
CCB or BB among patients experiencing ICH at younger
Sundbøll et al. BMC Neurology  (2015) 15:24 Page 7 of 8ages, although CIs were overlapping between strata of
age (Additional file 1: Table S7).
A major strength of our study was its large size, provid-
ing statistically precise estimates. The study’s population-
based design in the setting of a tax-supported universal
healthcare system with unfettered access and complete
follow-up of all patients largely eliminated selection bias.
As well, the complete and prospectively recorded hospital
and prescription histories reduced the risk of information
biases [28].
A potential limitation is that our stroke data were de-
rived from routine hospital discharge diagnoses, which
may introduce coding errors [17]. The positive predictive
value of acute stroke diagnoses in the DNRP has previ-
ously been validated and found to be approximately 97%
for ischemic stroke, 74% for ICH, and 67% for SAH [17].
Misclassification due to coding errors would most likely
be non-differential and thus could explain at least part
of the neutral results in this study. However, in sensitiv-
ity analyses restricted to CT or MRI-confirmed cases,
the results remained robust.
Because we classified unspecified strokes as ischemic
strokes, a few ICHs (approximately 6%) were inevitably
misclassified as ischemic strokes [17]. As we found no
overall association between CBB or BB use and ICH
mortality, such misclassification would bias the results
for ischemic stroke towards the null.
Data on reimbursed medications are virtually complete
in the prescription database [13], and neither CCB nor
BB are sold over-the-counter in Denmark. We therefore
identified all patients with redeemed prescriptions for
CBB and BB. Still, use of redeemed prescriptions as a
proxy for actual drug use may not always be accurate.
We did base drug exposure information on actual dis-
pensing at pharmacies rather than just on written pre-
scriptions [13]. Mortality data, as recorded in the CRS,
are virtually complete [14].
Although we controlled for several potential confound-
ing factors, we cannot exclude unmeasured confounding.
Moreover, we lacked information on smoking and blood
pressure levels. However, we did adjust for hospital diag-
noses of COPD and hypertension as proxy measures.
Smoking and hypertension may worsen prognosis after
stroke and are likely more prevalent among CCB and BB
users than among non-users. Thus, such potential con-
founding would have biased our estimates towards in-
creased mortality among CCB and BB users.
Although we adjusted for diagnoses of obesity, hospital-
based registration is likely to be incomplete and residual
confounding may persist. We lacked accurate information
on Body Mass Index, which is a major limitation for ad-
equately adjusting for obesity. However, we expect poten-
tial residual confounding to have negligible impact on the
results.Conclusions
Preadmission use of CCBs or BBs was not associated
with overall 30-day mortality among patients with ische-
mic stroke, ICH, or SAH.
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